➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
McKesson
Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Patent: 10,160,786

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,160,786
Title:Immunotherapy against several tumors, such as lung cancer, including NSCLC
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
Inventor(s): Weinschenk; Toni (Aichwald, DE), Walter; Steffen (Reutlingen, DE), Fritsche; Jens (Dusslingen, DE), Song; Colette (Ostfildern, DE), Singh; Harpreet (Munchen Schwabing, DE)
Assignee: Immatics Biotechnologies GMBH (Tuebingen, DE)
Application Number:16/100,858
Patent Claims:see list of patent claims

Details for Patent 10,160,786

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ⤷  Free Forever Trial Immatics Biotechnologies GMBH (Tuebingen, DE) 2033-08-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ⤷  Free Forever Trial Immatics Biotechnologies GMBH (Tuebingen, DE) 2033-08-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,160,786

Country Patent Number Estimated Expiration
Argentina 097241 ⤷  Free Forever Trial
Argentina 113131 ⤷  Free Forever Trial
Australia 2014304544 ⤷  Free Forever Trial
Australia 2018200389 ⤷  Free Forever Trial
Australia 2020220038 ⤷  Free Forever Trial
Australia 2020220039 ⤷  Free Forever Trial
Australia 2020220040 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Dow
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.